<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39394950</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2373-8227</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>12</Day></PubDate></JournalIssue><Title>ACS infectious diseases</Title><ISOAbbreviation>ACS Infect Dis</ISOAbbreviation></Journal><ArticleTitle>The HCoV-HKU1 N-Terminal Domain Binds a Wide Range of 9-<i>O</i>-Acetylated Sialic Acids Presented on Different Glycan Cores.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1021/acsinfecdis.4c00488</ELocationID><Abstract><AbstractText>Coronaviruses (CoVs) recognize a wide array of protein and glycan receptors by using the S1 subunit of the spike (S) glycoprotein. The S1 subunit contains two functional domains: the N-terminal domain (S1-NTD) and the C-terminal domain (S1-CTD). The S1-NTD of SARS-CoV-2, MERS-CoV, and HCoV-HKU1 possesses an evolutionarily conserved glycan binding cleft that facilitates weak interactions with sialic acids on cell surfaces. HCoV-HKU1 employs 9-<i>O</i>-acetylated α2-8-linked disialylated structures for initial binding, followed by TMPRSS2 receptor binding and virus-cell fusion. Here, we demonstrate that the HCoV-HKU1 NTD has a broader receptor binding repertoire than previously recognized. We presented HCoV-HKU1 NTD Fc chimeras on a nanoparticle system to mimic the densely decorated surface of HCoV-HKU1. These proteins were expressed by HEK293S GnTI<sup>-</sup> cells, generating species carrying Man-5 structures, often observed near the receptor binding site of CoVs. This multivalent presentation of high mannose-containing NTD proteins revealed a much broader receptor binding profile compared to that of its fully glycosylated counterpart. Using glycan microarrays, we observed that 9-<i>O</i>-acetylated α2-3-linked sialylated LacNAc structures are also bound, comparable to OC43 NTD, suggesting an evolutionarily conserved glycan-binding modality. Further characterization of receptor specificity indicated promiscuous binding toward 9-<i>O</i>-acetylated sialoglycans, independent of the glycan core (glycolipids, <i>N-</i> or <i>O</i>-glycans). We demonstrate that HCoV-HKU1 may employ additional sialoglycan receptors to trigger conformational changes in the spike glycoprotein to expose the S1-CTD for proteinaceous receptor binding.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tomris</LastName><ForeName>Ilhan</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Chemical Biology &amp; Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht 3584 CG, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kimpel</LastName><ForeName>Anne L M</ForeName><Initials>ALM</Initials><AffiliationInfo><Affiliation>Department of Chemical Biology &amp; Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht 3584 CG, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Ruonan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Chemical Biology &amp; Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht 3584 CG, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Woude</LastName><ForeName>Roosmarijn</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Chemical Biology &amp; Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht 3584 CG, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boons</LastName><ForeName>Geert-Jan P H</ForeName><Initials>GPH</Initials><AffiliationInfo><Affiliation>Department of Chemical Biology &amp; Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht 3584 CG, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Complex Carbohydrate Research Center, University of Georgia, 315 Riverbend Road, Athens, Georgia 30602, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zeshi</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Chemical Biology &amp; Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht 3584 CG, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Vries</LastName><ForeName>Robert P</ForeName><Initials>RP</Initials><Identifier Source="ORCID">0000-0002-1586-4464</Identifier><AffiliationInfo><Affiliation>Department of Chemical Biology &amp; Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht 3584 CG, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>ACS Infect Dis</MedlineTA><NlmUniqueID>101654580</NlmUniqueID><ISSNLinking>2373-8227</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>bioRxiv. 2024 May 24:2024.05.24.595699. doi: 10.1101/2024.05.24.595699</RefSource><PMID Version="1">38826377</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HCoV-HKU1</Keyword><Keyword MajorTopicYN="N">coronavirus</Keyword><Keyword MajorTopicYN="N">glycans</Keyword><Keyword MajorTopicYN="N">ligand</Keyword><Keyword MajorTopicYN="N">multivalency</Keyword><Keyword MajorTopicYN="N">receptor binding</Keyword><Keyword MajorTopicYN="N">sialic acid</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>12</Day><Hour>21</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>12</Day><Hour>21</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>12</Day><Hour>8</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39394950</ArticleId><ArticleId IdType="doi">10.1021/acsinfecdis.4c00488</ArticleId></ArticleIdList></PubmedData></PubmedArticle>